Bolt Biotherapeutics Inc (BOLT) Stock Price, Quote & News

Company Profile

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 665 9295

Website: www.boltbio.com

Address:

900 Chesapeake Drive, Redwood City, United States

skyrockets_Inc Feb. 20 at 5:18 PM

$BOLT Been slowly buying bits when it dropped into 4's. Waiting now to see how price moves

0 · Reply

PriceActionSocietytrades Feb. 19 at 7:39 PM

$BOLT

0 · Reply

SheriffGrover Feb. 19 at 2:04 PM

$BOLT Marketwire quote from Genmab CEO : He points out that Genmab is still looking for smaller complementary acquisitions - Genmab's CEO calls them "token" acquisitions. - But we are not in the market with a view to major acquisitions. - Now it's about focus and execution, says Jan van de Winkel. Now let's hope and pray BOLT is in the picture !!;o)

1 · Reply

SheriffGrover Feb. 18 at 7:37 PM

$BOLT Hmmmmm new all time low ....... geezzzzz

1 · Reply

trendricky Feb. 17 at 8:26 AM

$BOLT Pre-revenue EV or tech; speculative

0 · Reply

Kevingeorge Feb. 14 at 7:52 PM

$BOLT swear its been a rough two years hopefully this just hits 17 soon!

0 · Reply

SheriffGrover Feb. 10 at 3:43 PM

$BOLT well enough now BOLT ..... come on ...

1 · Reply

ZoneRaider Feb. 9 at 11:16 AM

$BOLT is an electric vehicle charging or automotive technology company; it faces the classic challenge of building infrastructure ahead of demand, requiring large capital outlays with uncertain near-term returns.

1 · Reply

jschor88 Feb. 6 at 2:38 PM

$BOLT 👀

0 · Reply

JL_TradeZ Feb. 5 at 3:15 PM

🚨SPECIAL PLAY $BOLT Seeing a heavy cluster of Form 4 insider buys here. The CEO, COO, and multiple directors are all stepping in again after the pullback. Cash is over 30M with a market cap around 10M, which stands out. Float is small, and institutions are still involved. This cooled off after the run but didn’t fall apart. If it goes, I’m looking toward 7-8+ and extension if momentum rotates back into small-cap biotech

3 · Reply

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 1, 2025, 4:05 PM EDT - 5 months ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Aug 14, 2025, 4:05 PM EDT - 6 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 10 months ago

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 10 months ago

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Apr 30, 2025, 4:05 PM EDT - 10 months ago

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 10 months ago

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Mar 24, 2025, 4:20 PM EDT - 11 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Feb 11, 2025, 4:05 PM EST - 1 year ago

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Nov 7, 2024, 10:00 AM EST - 1 year ago

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Sep 6, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Announces Changes to its Board of Directors

Sep 4, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 2, 2024, 11:11 AM EDT - 1 year ago

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

$Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions$

Sep 2, 2024, 11:00 AM EDT - 1 year ago

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

Aug 31, 2024, 11:25 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

$Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm$

Aug 31, 2024, 11:00 AM EDT - 1 year ago

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

Aug 29, 2024, 8:49 PM EDT - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Aug 28, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Join A Lawsuit For Securities Fraud Against Bolt Biotherapeutics Inc

$A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm$

Aug 27, 2024, 11:00 AM EDT - 1 year ago

A Case Has Been Filed Against Bolt Biotherapeutics Inc For Securities Law Infractions And Stakeholders Are Encouraged To Contact The Schall Law Firm

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 26, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Actively Participate Bolt Biotherapeutics, Inc.

Jul 25, 2024, 10:00 AM EDT - 1 year ago

BOLT Investors Have Opportunity to Lead Bolt Biotherapeutics, Inc.

Jul 19, 2024, 11:10 AM EDT - 1 year ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on September 3, 2024 in Bolt Lawsuit

Jul 3, 2024, 4:47 PM EDT - 1 year ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bolt Biotherapeutics, Inc. (BOLT)

Jun 24, 2024, 3:36 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

May 17, 2024, 8:37 PM EDT - 1 year ago

Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript

skyrockets_Inc Feb. 20 at 5:18 PM

$BOLT Been slowly buying bits when it dropped into 4's. Waiting now to see how price moves

0 · Reply

PriceActionSocietytrades Feb. 19 at 7:39 PM

$BOLT

0 · Reply

SheriffGrover Feb. 19 at 2:04 PM

1 · Reply

SheriffGrover Feb. 18 at 7:37 PM

$BOLT Hmmmmm new all time low ....... geezzzzz

1 · Reply

trendricky Feb. 17 at 8:26 AM

$BOLT Pre-revenue EV or tech; speculative

0 · Reply

Kevingeorge Feb. 14 at 7:52 PM

$BOLT swear its been a rough two years hopefully this just hits 17 soon!

0 · Reply

SheriffGrover Feb. 10 at 3:43 PM

$BOLT well enough now BOLT ..... come on ...

1 · Reply

ZoneRaider Feb. 9 at 11:16 AM

1 · Reply

jschor88 Feb. 6 at 2:38 PM

$BOLT 👀

0 · Reply

JL_TradeZ Feb. 5 at 3:15 PM

3 · Reply

MstrminD Feb. 4 at 9:41 PM

$BOLT

0 · Reply

skyrockets_Inc Feb. 4 at 6:05 PM

$BOLT Entire market getting smashed daily, this needs to hold 5.60+

0 · Reply

NVDAMillionaire Feb. 4 at 4:07 PM

$BOLT Excellent article that nails exactly where BOLT stands right now. So if you want to update your BOLT knowledge or get acquainted with BOLT, this is a must read. https://everyticker.com/quote/BOLT/analysis/bolt-biotherapeutics-sharpening-the-immuno-oncology-edge-with-next-gen-isacs-nasdaq-bolt

0 · Reply

HartFoundation Feb. 3 at 6:38 PM

$BOLT bought another 200 shares on sale.

0 · Reply

HartFoundation Jan. 29 at 4:47 PM

$BOLT bought 200 more shares.

0 · Reply

skyrockets_Inc Jan. 28 at 8:32 PM

$BOLT 7.08/share. It wants to break this level. If it can, we moon.

0 · Reply

HartFoundation Jan. 27 at 6:29 PM

$BOLT Been eyeing this forever, finally opened a position. GLTA.

1 · Reply

skyrockets_Inc Jan. 27 at 4:31 PM

$BOLT 50 officially crossed 100 . 6.93/share and climbing on slow healthy volume. The explosion to the upside has to be soon. $15/share in cash, no debt, 50% insider and tute ownership, 2 assets in current partnership deals w/ big pharma Genmab and Toray, 3 assets (1 P1 and 2 pre-clincal) available for partnering, and main asset in Phase 1 dose escalation trial w/ initial data in Q3, already shown a strong immune response back in November. 1.92m SUPER LOW FLOAT. Epic set up :)

0 · Reply

SuperGreenToday Jan. 26 at 5:27 PM

$BOLT

0 · Reply

skyrockets_Inc Jan. 26 at 4:23 PM

$BOLT 50 crossing 100, approaching 200SMA. Fireworks coming soon w/ volume.

0 · Reply

Red2Profit Jan. 24 at 4:42 PM

$BOLT Strap in friends. About to break a weekly double bottom and falling wedge. Conservative target 10.39. Break those 52 week highs (12.60) and volume and we could see 25-32. Let's see how next week starts. Break and retest of 6.69 is key

1 · Reply

skyrockets_Inc Jan. 23 at 8:05 PM

$BOLT This one is days away from exploding. 50 about to cross 100 SMA + volume

1 · Reply

Market Cap	8.96M
Revenue (ttm)	7.69M
Net Income (ttm)	-63.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-820.81%
Debt to Equity Ratio	0.00

Volume	12,600
Avg Vol	41,754
Day's Range	N/A - N/A
Shares Out	1.92M
Stochastic %K	19%
Beta	0.92
Analysts	Sell
Price Target	$6.00